Patients rate their symptoms after starting secukinumab for hidradenitis suppurativa
NCT ID NCT06444087
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 192 adults with hidradenitis suppurativa (a painful skin condition) who are starting secukinumab as part of their normal care. Researchers will ask patients to rate their pain, oozing, and bad smell after 12 months. The goal is to understand how the drug affects symptoms from the patient's point of view, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
secukinumab
What this could lead to
If successful, this study could show how well secukinumab works from the patient's perspective, helping doctors better understand its real-world benefits for hidradenitis suppurativa.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors other than the drug. It only follows patients for 12 months and does not test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Nice, France, 06000, France
-
Novartis Investigative Site
Antony, 92160, France
-
Novartis Investigative Site
Bordeaux, 33075, France
-
Novartis Investigative Site
Brest, 29609, France
-
Novartis Investigative Site
Calais, 62100, France
-
Novartis Investigative Site
Dijon, 21000, France
-
Novartis Investigative Site
La Rochelle, 17019, France
-
Novartis Investigative Site
Le Mans, 72000, France
-
Novartis Investigative Site
Lille, 59037, France
-
Novartis Investigative Site
Lorient, 56322, France
-
Novartis Investigative Site
Lyon, 69003, France
-
Novartis Investigative Site
Marseille, 13008, France
-
Novartis Investigative Site
Martigues, 13500, France
-
Novartis Investigative Site
Montpellier, 34090, France
-
Novartis Investigative Site
Nantes, 44093, France
-
Novartis Investigative Site
Paris, 75014, France
-
Novartis Investigative Site
Rodez, 12000, France
-
Novartis Investigative Site
Rouen, 76031, France
-
Novartis Investigative Site
Saint-Mandé, 94160, France
-
Novartis Investigative Site
Saint-Pierre, 97410, France
-
Novartis Investigative Site
Toulouse, 31400, France
-
Novartis Investigative Site
Vannes, 56000, France